Klinik Araştırma

Could ELABELA be a Protective Biomarker in Patients with Abnormal Uterine Bleeding?

Cilt: 6 Sayı: 3 24 Eylül 2024
PDF İndir
EN

Could ELABELA be a Protective Biomarker in Patients with Abnormal Uterine Bleeding?

Abstract

Aim: Abnormal uterine bleeding (AUB) is a health problem characterized by various symptoms such as heavy and prolonged menstrual bleeding, affecting approximately 30% of female patients both physiologically and psychologically. The objective of this study was to assess serum Elabela (ELA) concentrations in women aged 18 and above diagnosed with functional AUB, and to compare these concentrations with those of healthy women. Material and Method: This prospective case-control study was performed from August 18, 2022 to December 30, 2022. This was a cross-sectional study including 50 women who applied to the gynecology service of Malatya Turgut Özal Training and Research Hospital with complaints of AUB and 50 women without AUB who underwent gynecological examination. The presence of AUB in patients was determined based on clinical examination conducted by a gynecologist and medical records. Demographic and clinical characteristics were recorded. Serum ELA levels were determined by commercial ELISA kit. Results: Serum ELA levels was significantly lower in patients with AUB (581.54±272.25 pg/mL) compared to the healthy group (744.55±300.31 pg/mL, p=0.005). In this study, ELA in patients with AUB showed 98% sensitivity and 80% specificity with a cut off value of 411.41 pg/mL (area under the curve [AUC], 68.1%; p=0.002). Conclusion: Serum ELA levels in patients with AUB were significantly lower than in healthy women. These results show that ELA is a good predictor of the pathophysiological process of AUB.

Keywords

Destekleyen Kurum

No Support

Proje Numarası

No Project

Etik Beyan

This study was approved by the Ethics Committee of Malatya Turgut Özal University Clinical Research Ethics Committee (18.08.2022, Approval No:2022/37).

Teşekkür

No

Kaynakça

  1. Mutakha GS, Mwaliko E, Kirwa P. Clinical bleeding patterns and management techniques of abnormal uterine bleeding at a teaching and referral hospital in Western Kenya. Plos One. 2020;15:e0243166.
  2. Livingstone M, Frase IS. Mechanisms of abnormal uterine bleeding. Hum Reprod Update. 2002;8:60-7.
  3. Whitaker L, Critchley HOD. Abnormal uterine bleeding. Best Pract & Res Clin Obstet and Gynaecol. 2016; 34:54-65.
  4. Matteson KA, Boardman LA, Munro MG, Clark MA. Abnormal uterine bleeding: a review of patient-based outcome measures. Fertil and Steril. 2009;92:205-16.
  5. Crawford NM, Pritchard DA, Herring AH, Steiner AZ. Prospective evaluation of the impact of intermenstrual bleeding on natural fertility. Fertil and Steril. 2016;105:1294-300.
  6. Albers JR, Hull SK, Wesley RM. Anormal uterine bleeding. Am Fam Physician. 2004;69:1915-26.
  7. Wouk N, Helton M. Abnormal uterine bleeding in premenopausal women. Am Fam Physician. 2019;99:435-43.
  8. Marnach ML, Laughlin-Tammaso SK. Evaluation and management of abnormal uterine bleeding. Mayo Clin Proc. 2019;94:326-35.

Ayrıntılar

Birincil Dil

İngilizce

Konular

Tıbbi Biyokimya ve Metabolomik (Diğer)

Bölüm

Klinik Araştırma

Yayımlanma Tarihi

24 Eylül 2024

Gönderilme Tarihi

30 Mayıs 2024

Kabul Tarihi

1 Ağustos 2024

Yayımlandığı Sayı

Yıl 2024 Cilt: 6 Sayı: 3

Kaynak Göster

AMA
1.Kıran TR, Karabulut U, Otlu Ö, Yıldırım E, Erdem M, İnceoğlu F. Could ELABELA be a Protective Biomarker in Patients with Abnormal Uterine Bleeding? Med Records. 2024;6(3):413-418. doi:10.37990/medr.1490041